- Oops!Something went wrong.Please try again later.
Apple's (NASDAQ: AAPL) stock price climbed 3.2% on Tuesday, despite a sharp fall in the major market indices. Investors were startled by comments from Federal Reserve Chair Jerome Powell, which suggested that the powerful central bank could pull back on stimulus measures sooner than it forecasted. Many analysts had expected the Fed to adopt a more supportive stance toward the economy after health officials detected a worrisome new coronavirus strain that threatens to derail the market's recovery.
Wall Street has known its share of legends, but few of them have made as big a splash as “the Man Who Broke the Bank of England.” That nickname belongs to George Soros who earned the tag after famously betting against the British Pound in 1992; following the Black Wednesday crash, the hedge fund manager pocketed $1 billion in a single day. This is the stuff that Wall Street legends are made of. By then Soros was already incredibly successful and in the midst of steering his Quantum Fund to decad
Investors are rattled by the FDA's request for an out-of-the-ordinary meeting dedicated to scrutinizing the company's latest drug approval request.
Satya Nadella sold 838,584 shares between Nov. 23 and Nov. 24. The move comes a month before Washington state's capital gains tax goes into effect.
Multiple factors are making investors in the EV stock very jittery.
Fed Chair Powell and Treasury Secretary Yellen give their testimonies to the Senate Banking Committee on the outlook for inflation.
On Nov. 15, institutional investors and hedge funds with at least $100 million in assets under management were required to file Form 13F with the Securities and Exchange Commission (SEC). With the latest round of 13Fs, one thing stands out: billionaires were buying stocks hand over fist. Billionaire Ken Griffin is a wildly successful investor who's known for extracting big wins from his firms' options positions.
Shares of Vir Biotechnology (NASDAQ: VIR) were soaring 18.5% as of 11:08 a.m. ET on Tuesday. The big gain came after H.C. Wainwright analyst Patrick Trucchio boosted his price target on Vir from $135 to $200. Several analysts are bullish about Vir's prospects.
You only have a couple more days to profit in two different ways from tax-loss selling. From a statistical point of view, that means you’re finding a security whose gyrations can explain or predict at least half of the movements of your tax loss sale candidate.
The shares were one of the few bright spots as markets sold off sharply, with almost every other major tech stock trading in the red.
As I was extolling the virtues of Social Security’s 5.9% COLA, the Centers for Medicare and Medicaid Services (CMS) announced that they were increasing the premium for Medicare Part B by 14.5%. As a reminder, Medicare is composed of two programs. Part A, Hospital Insurance (HI), which covers inpatient hospital services, skilled nursing facilities, home healthcare, and hospice care.
Those following along with Clover Health Investments, Corp. ( NASDAQ:CLOV ) will no doubt be intrigued by the recent...
AT&T Inc. shares are leading a wireless selloff Tuesday after the company gave a presentation at an investor conference that one analyst said "reinforced market fears" about what its customer-acquisition spending could mean for broader industry trends.
The total U.S. equity market capitalization is about 215% of U.S. gross domestic product---the highest level ever. Sky-high market caps to GDP have come just before hard times for Wall Street.
Yahoo Finance Live's Julie Hyman breaks down some of the leading national headlines including Microsoft CED Satya Nadella selling half his stake in the company, Amazon allowing a new unionization vote in Alabama, and Lululemon firing back at Peloton with patent infringement lawsuit.
CEO Satya Nadella sold about half his stake in the software company, according to recent filings with the Securities and Exchange Commission.
Bret Taylor, who has been president and chief operating officer, was promoted to co-CEO with Marc Benioff.
Shares of Seres Therapeutics (NASDAQ: MCRB) climbed more than 21% on Tuesday. The biotech stock, which closed at $8.82 on Monday, opened at $8.63 on Tuesday, then took off, climbing to a daily high of $10.78 in the afternoon. The move was in direct contrast to the general market trend with both the Dow Jones Industrial Average and S&P 500 index down for the day.
Andrew Slimmon, Morgan Stanley Investment Management Managing Director and Sr. Portfolio Manager, joins Yahoo Finance to make sense of Tuesday's sell-off and preivew what to expect from the markets in 2022.
What kind of stocks stir up controversy like no other? Penny stocks. These tickers trading for less than $5 per share have earned a reputation as some of the most divisive names on Wall Street, with these plays either met with open arms or given the cold shoulder. It’s understandable why some investors are wary. Those opposed are quick to point out that there could be a very real reason these stocks are changing hands for pocket change, with the low share prices often masking obstacles like weak